 Natalie Serkova
Concepts (676)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Magnetic Resonance Spectroscopy | 35 | 2014 | 472 | 2.990 |
Why?
| | Cyclosporine | 18 | 2012 | 160 | 2.600 |
Why?
| | Immunosuppressive Agents | 21 | 2013 | 633 | 2.200 |
Why?
| | Sirolimus | 17 | 2013 | 181 | 1.900 |
Why?
| | Magnetic Resonance Imaging | 24 | 2020 | 3013 | 1.870 |
Why?
| | Pyrimidines | 8 | 2017 | 372 | 1.330 |
Why?
| | Piperazines | 6 | 2009 | 309 | 1.290 |
Why?
| | Metabolomics | 11 | 2021 | 508 | 1.260 |
Why?
| | Glucose | 14 | 2021 | 894 | 1.170 |
Why?
| | Contrast Media | 6 | 2017 | 346 | 1.130 |
Why?
| | Brain | 13 | 2020 | 2309 | 1.110 |
Why?
| | Antineoplastic Agents | 15 | 2022 | 1872 | 1.100 |
Why?
| | Energy Metabolism | 13 | 2019 | 717 | 1.100 |
Why?
| | Biomarkers | 14 | 2019 | 3389 | 1.020 |
Why?
| | Neoplasms | 14 | 2017 | 2082 | 1.000 |
Why?
| | Liver | 12 | 2020 | 1630 | 1.000 |
Why?
| | Drug Resistance, Neoplasm | 6 | 2017 | 636 | 0.940 |
Why?
| | Animals | 95 | 2023 | 31162 | 0.930 |
Why?
| | Neoplasms, Experimental | 3 | 2020 | 149 | 0.860 |
Why?
| | Reperfusion Injury | 11 | 2014 | 251 | 0.760 |
Why?
| | Biomarkers, Tumor | 10 | 2020 | 1029 | 0.730 |
Why?
| | Rats | 29 | 2015 | 4829 | 0.690 |
Why?
| | Multimodal Imaging | 1 | 2020 | 89 | 0.690 |
Why?
| | Protein Kinase Inhibitors | 10 | 2018 | 779 | 0.690 |
Why?
| | Proton Magnetic Resonance Spectroscopy | 2 | 2019 | 20 | 0.670 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 5 | 2014 | 93 | 0.630 |
Why?
| | Cell Line, Tumor | 25 | 2023 | 2690 | 0.630 |
Why?
| | Ferrosoferric Oxide | 3 | 2019 | 22 | 0.630 |
Why?
| | Metabolome | 5 | 2019 | 275 | 0.630 |
Why?
| | Nanoparticles | 4 | 2017 | 308 | 0.600 |
Why?
| | Ischemic Preconditioning | 2 | 2009 | 26 | 0.580 |
Why?
| | Hypoxia | 6 | 2015 | 919 | 0.550 |
Why?
| | Phospholipids | 7 | 2010 | 192 | 0.520 |
Why?
| | Aging | 5 | 2020 | 1601 | 0.520 |
Why?
| | Mice | 45 | 2023 | 14679 | 0.520 |
Why?
| | Fusion Proteins, bcr-abl | 5 | 2015 | 60 | 0.520 |
Why?
| | Everolimus | 12 | 2013 | 61 | 0.500 |
Why?
| | Rats, Wistar | 11 | 2010 | 366 | 0.500 |
Why?
| | Glutathione | 9 | 2023 | 291 | 0.490 |
Why?
| | Body Fluids | 5 | 2019 | 56 | 0.480 |
Why?
| | Inositol | 4 | 2021 | 23 | 0.470 |
Why?
| | Glutamine | 6 | 2013 | 90 | 0.470 |
Why?
| | Mitochondria | 7 | 2014 | 735 | 0.450 |
Why?
| | Brain Injuries | 3 | 2014 | 449 | 0.450 |
Why?
| | Epilepsy, Post-Traumatic | 1 | 2013 | 3 | 0.450 |
Why?
| | Organ Specificity | 4 | 2013 | 262 | 0.450 |
Why?
| | Positron-Emission Tomography | 10 | 2020 | 260 | 0.440 |
Why?
| | Nephritis | 1 | 2013 | 20 | 0.440 |
Why?
| | Lupus Nephritis | 2 | 2011 | 52 | 0.430 |
Why?
| | Apoptosis | 14 | 2022 | 2288 | 0.420 |
Why?
| | Imatinib Mesylate | 7 | 2014 | 62 | 0.410 |
Why?
| | Disease Models, Animal | 16 | 2023 | 3470 | 0.410 |
Why?
| | Leukemia | 2 | 2018 | 208 | 0.400 |
Why?
| | Humans | 71 | 2023 | 113531 | 0.400 |
Why?
| | Placenta | 3 | 2009 | 627 | 0.400 |
Why?
| | Oxidative Stress | 5 | 2010 | 1065 | 0.380 |
Why?
| | Kidney | 7 | 2023 | 1179 | 0.380 |
Why?
| | Reactive Oxygen Species | 5 | 2013 | 516 | 0.380 |
Why?
| | Time Factors | 12 | 2013 | 6032 | 0.380 |
Why?
| | Metabolism | 3 | 2017 | 35 | 0.380 |
Why?
| | Drug Monitoring | 3 | 2013 | 184 | 0.370 |
Why?
| | Cerebellar Neoplasms | 2 | 2023 | 130 | 0.360 |
Why?
| | Benzamides | 6 | 2009 | 168 | 0.360 |
Why?
| | Seizures | 1 | 2013 | 335 | 0.360 |
Why?
| | Kidney Diseases | 2 | 2020 | 348 | 0.360 |
Why?
| | Astrocytes | 4 | 2015 | 156 | 0.360 |
Why?
| | Medulloblastoma | 2 | 2023 | 172 | 0.350 |
Why?
| | Liver Diseases | 2 | 2010 | 254 | 0.350 |
Why?
| | Diagnostic Imaging | 2 | 2011 | 278 | 0.340 |
Why?
| | Cell Proliferation | 13 | 2022 | 2164 | 0.340 |
Why?
| | Molecular Targeted Therapy | 2 | 2017 | 345 | 0.330 |
Why?
| | Liver Transplantation | 2 | 2007 | 693 | 0.330 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 4 | 2017 | 248 | 0.330 |
Why?
| | Molecular Probes | 1 | 2009 | 30 | 0.330 |
Why?
| | Prostatic Neoplasms | 5 | 2016 | 911 | 0.320 |
Why?
| | Glucose Transporter Type 1 | 1 | 2009 | 43 | 0.320 |
Why?
| | Lactic Acid | 7 | 2013 | 269 | 0.310 |
Why?
| | Silymarin | 4 | 2016 | 194 | 0.310 |
Why?
| | Complement C3b | 2 | 2023 | 31 | 0.300 |
Why?
| | Tomography, X-Ray Computed | 3 | 2020 | 2269 | 0.300 |
Why?
| | Adaptation, Physiological | 2 | 2009 | 465 | 0.300 |
Why?
| | Spermine | 1 | 2008 | 25 | 0.300 |
Why?
| | K562 Cells | 4 | 2009 | 73 | 0.300 |
Why?
| | Citric Acid | 1 | 2008 | 28 | 0.300 |
Why?
| | Xenograft Model Antitumor Assays | 9 | 2019 | 693 | 0.300 |
Why?
| | Graft Rejection | 5 | 2010 | 508 | 0.300 |
Why?
| | Head and Neck Neoplasms | 3 | 2019 | 423 | 0.300 |
Why?
| | Kidney Transplantation | 4 | 2010 | 537 | 0.290 |
Why?
| | Hibernation | 2 | 2014 | 72 | 0.290 |
Why?
| | Drug Design | 2 | 2007 | 146 | 0.290 |
Why?
| | Colorectal Neoplasms | 4 | 2018 | 592 | 0.280 |
Why?
| | Altitude | 3 | 2009 | 404 | 0.280 |
Why?
| | Male | 45 | 2022 | 55112 | 0.280 |
Why?
| | Prostate | 1 | 2008 | 157 | 0.280 |
Why?
| | Creatine | 3 | 2021 | 51 | 0.270 |
Why?
| | Choline | 2 | 2009 | 106 | 0.270 |
Why?
| | Pneumonia | 2 | 2011 | 561 | 0.270 |
Why?
| | Signal Transduction | 11 | 2019 | 4439 | 0.270 |
Why?
| | Liver Failure | 1 | 2007 | 72 | 0.270 |
Why?
| | Dietary Supplements | 3 | 2023 | 459 | 0.270 |
Why?
| | Brain Neoplasms | 4 | 2020 | 964 | 0.260 |
Why?
| | Drug Therapy | 1 | 2006 | 74 | 0.260 |
Why?
| | Sex Characteristics | 1 | 2010 | 633 | 0.260 |
Why?
| | Brain Injuries, Traumatic | 2 | 2023 | 295 | 0.260 |
Why?
| | Glioma | 3 | 2020 | 284 | 0.260 |
Why?
| | Adenosine Triphosphate | 5 | 2009 | 426 | 0.260 |
Why?
| | Interleukin-1beta | 1 | 2008 | 364 | 0.250 |
Why?
| | Blotting, Western | 6 | 2019 | 1128 | 0.250 |
Why?
| | fms-Like Tyrosine Kinase 3 | 2 | 2016 | 42 | 0.250 |
Why?
| | Neovascularization, Pathologic | 4 | 2018 | 280 | 0.240 |
Why?
| | Obesity | 3 | 2006 | 2501 | 0.240 |
Why?
| | Protein Kinases | 2 | 2004 | 300 | 0.240 |
Why?
| | Macrolides | 2 | 2013 | 56 | 0.240 |
Why?
| | Carcinoma, Hepatocellular | 2 | 2020 | 210 | 0.240 |
Why?
| | Sepsis | 4 | 2013 | 505 | 0.240 |
Why?
| | Tumor Suppressor Protein p53 | 2 | 2022 | 443 | 0.230 |
Why?
| | Organ Transplantation | 2 | 2004 | 157 | 0.230 |
Why?
| | Rats, Sprague-Dawley | 9 | 2015 | 2139 | 0.230 |
Why?
| | Protein-Tyrosine Kinases | 3 | 2014 | 390 | 0.230 |
Why?
| | Myocardium | 2 | 2013 | 906 | 0.230 |
Why?
| | Glycolysis | 4 | 2010 | 223 | 0.230 |
Why?
| | Neurotoxicity Syndromes | 1 | 2004 | 14 | 0.230 |
Why?
| | Cell Transformation, Neoplastic | 3 | 2015 | 305 | 0.220 |
Why?
| | Lung Transplantation | 3 | 2000 | 241 | 0.220 |
Why?
| | Drug Interactions | 5 | 2012 | 332 | 0.220 |
Why?
| | Autophagy | 2 | 2018 | 235 | 0.220 |
Why?
| | Chromatography, High Pressure Liquid | 4 | 2009 | 463 | 0.220 |
Why?
| | Autolysis | 1 | 2003 | 3 | 0.210 |
Why?
| | Gene Expression Regulation, Neoplastic | 5 | 2020 | 1140 | 0.210 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2008 | 1106 | 0.210 |
Why?
| | Myocardial Reperfusion Injury | 1 | 2003 | 95 | 0.210 |
Why?
| | Fatty Liver | 1 | 2005 | 209 | 0.210 |
Why?
| | Deoxycytidine | 2 | 2017 | 137 | 0.210 |
Why?
| | Glomerulonephritis | 1 | 2023 | 45 | 0.200 |
Why?
| | Phosphates | 2 | 2001 | 154 | 0.200 |
Why?
| | Colonic Neoplasms | 3 | 2013 | 210 | 0.200 |
Why?
| | In Vitro Techniques | 5 | 2016 | 996 | 0.190 |
Why?
| | Lung | 8 | 2018 | 3497 | 0.190 |
Why?
| | Specimen Handling | 1 | 2003 | 152 | 0.190 |
Why?
| | Carbon Isotopes | 3 | 2009 | 110 | 0.190 |
Why?
| | Antineoplastic Agents, Phytogenic | 2 | 2013 | 180 | 0.190 |
Why?
| | Proto-Oncogene Proteins c-mdm2 | 1 | 2022 | 55 | 0.190 |
Why?
| | Mice, Nude | 8 | 2016 | 625 | 0.190 |
Why?
| | Image Processing, Computer-Assisted | 3 | 2019 | 681 | 0.190 |
Why?
| | Blood-Brain Barrier | 2 | 2013 | 102 | 0.190 |
Why?
| | Gene Expression Regulation | 4 | 2019 | 2293 | 0.190 |
Why?
| | Chemoradiotherapy | 2 | 2019 | 187 | 0.190 |
Why?
| | Radiation Tolerance | 1 | 2022 | 91 | 0.190 |
Why?
| | Hydroxamic Acids | 2 | 2011 | 80 | 0.180 |
Why?
| | Tendinopathy | 1 | 2021 | 22 | 0.180 |
Why?
| | Photoacoustic Techniques | 1 | 2020 | 3 | 0.180 |
Why?
| | Rhabdoid Tumor | 1 | 2022 | 80 | 0.180 |
Why?
| | Dose-Response Relationship, Drug | 8 | 2012 | 1822 | 0.180 |
Why?
| | Magnetite Nanoparticles | 2 | 2011 | 26 | 0.180 |
Why?
| | Insulin Resistance | 2 | 2019 | 1068 | 0.180 |
Why?
| | TOR Serine-Threonine Kinases | 5 | 2018 | 357 | 0.180 |
Why?
| | Anterior Cruciate Ligament Injuries | 1 | 2022 | 130 | 0.180 |
Why?
| | Mass Spectrometry | 4 | 2011 | 616 | 0.180 |
Why?
| | Tomography, Emission-Computed, Single-Photon | 1 | 2020 | 75 | 0.170 |
Why?
| | Heat-Shock Proteins | 3 | 2006 | 112 | 0.170 |
Why?
| | Anticarcinogenic Agents | 2 | 2011 | 66 | 0.170 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 5 | 2014 | 1356 | 0.170 |
Why?
| | Polycomb Repressive Complex 1 | 1 | 2020 | 38 | 0.170 |
Why?
| | Osteoarthritis | 1 | 2022 | 168 | 0.170 |
Why?
| | Perfusion | 3 | 2009 | 147 | 0.170 |
Why?
| | Mammary Glands, Animal | 2 | 2014 | 116 | 0.170 |
Why?
| | Camptothecin | 2 | 2013 | 95 | 0.170 |
Why?
| | Transcriptional Elongation Factors | 1 | 2020 | 31 | 0.170 |
Why?
| | Particle Accelerators | 1 | 2019 | 9 | 0.170 |
Why?
| | Lactation | 2 | 2014 | 147 | 0.170 |
Why?
| | Heart | 1 | 2003 | 609 | 0.170 |
Why?
| | Complement Factor H | 1 | 2020 | 60 | 0.170 |
Why?
| | Electromagnetic Phenomena | 1 | 2019 | 20 | 0.170 |
Why?
| | Histone Deacetylase Inhibitors | 2 | 2011 | 197 | 0.170 |
Why?
| | Scavenger Receptors, Class A | 1 | 2019 | 8 | 0.170 |
Why?
| | Fatty Acids | 2 | 2015 | 380 | 0.170 |
Why?
| | DNA Repair | 1 | 2021 | 182 | 0.170 |
Why?
| | Chromosomes, Human, Pair 1 | 1 | 2019 | 66 | 0.160 |
Why?
| | Brain Chemistry | 1 | 2000 | 112 | 0.160 |
Why?
| | Tumor Microenvironment | 2 | 2019 | 428 | 0.160 |
Why?
| | Endoplasmic Reticulum Stress | 3 | 2014 | 91 | 0.160 |
Why?
| | Fluorodeoxyglucose F18 | 2 | 2021 | 115 | 0.160 |
Why?
| | Infratentorial Neoplasms | 1 | 2019 | 44 | 0.160 |
Why?
| | Macrophages, Peritoneal | 1 | 2019 | 88 | 0.160 |
Why?
| | Proto-Oncogene Proteins c-myc | 2 | 2021 | 115 | 0.160 |
Why?
| | Precursor Cells, B-Lymphoid | 2 | 2017 | 34 | 0.160 |
Why?
| | Receptor, EphB4 | 1 | 2019 | 22 | 0.160 |
Why?
| | Ephrin-B2 | 1 | 2019 | 34 | 0.160 |
Why?
| | Lipogenesis | 2 | 2016 | 56 | 0.160 |
Why?
| | Angiogenesis Inhibitors | 2 | 2011 | 212 | 0.160 |
Why?
| | Histones | 2 | 2020 | 528 | 0.150 |
Why?
| | Neoplasm Proteins | 2 | 2020 | 381 | 0.150 |
Why?
| | Whey Proteins | 1 | 2018 | 5 | 0.150 |
Why?
| | Female | 28 | 2022 | 59115 | 0.150 |
Why?
| | Glucose Clamp Technique | 1 | 2019 | 181 | 0.150 |
Why?
| | Phosphocreatine | 3 | 2004 | 36 | 0.150 |
Why?
| | Smad4 Protein | 1 | 2018 | 34 | 0.150 |
Why?
| | Liver Neoplasms | 2 | 2020 | 504 | 0.150 |
Why?
| | Salivary Gland Neoplasms | 1 | 2018 | 30 | 0.150 |
Why?
| | Tracheal Stenosis | 1 | 2018 | 18 | 0.150 |
Why?
| | Anilides | 1 | 2018 | 67 | 0.150 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 3 | 2013 | 227 | 0.150 |
Why?
| | Polyenes | 1 | 1997 | 7 | 0.150 |
Why?
| | Ependymoma | 1 | 2019 | 152 | 0.150 |
Why?
| | Cells, Cultured | 6 | 2019 | 3802 | 0.150 |
Why?
| | Macrophages | 3 | 2019 | 1233 | 0.150 |
Why?
| | Acute Lung Injury | 2 | 2011 | 266 | 0.150 |
Why?
| | Pancreatic Neoplasms | 2 | 2017 | 721 | 0.150 |
Why?
| | Fibroblasts | 2 | 2016 | 827 | 0.140 |
Why?
| | Rats, Zucker | 3 | 2006 | 27 | 0.140 |
Why?
| | Kinetics | 3 | 2009 | 1528 | 0.140 |
Why?
| | Mucin-1 | 1 | 2017 | 18 | 0.140 |
Why?
| | Neuroprotective Agents | 1 | 2018 | 100 | 0.140 |
Why?
| | PTEN Phosphohydrolase | 1 | 2018 | 140 | 0.140 |
Why?
| | Folic Acid Deficiency | 1 | 2017 | 48 | 0.140 |
Why?
| | Drug Synergism | 5 | 2013 | 312 | 0.140 |
Why?
| | Blood Glucose | 4 | 2019 | 1823 | 0.140 |
Why?
| | Lactates | 3 | 2006 | 77 | 0.140 |
Why?
| | Adenosine Diphosphate | 2 | 2009 | 76 | 0.140 |
Why?
| | Transcription Factors | 5 | 2014 | 1497 | 0.130 |
Why?
| | Inflammation Mediators | 1 | 2019 | 469 | 0.130 |
Why?
| | Quinazolines | 2 | 2008 | 239 | 0.130 |
Why?
| | Ataxia Telangiectasia Mutated Proteins | 1 | 2016 | 62 | 0.130 |
Why?
| | Glucosephosphate Dehydrogenase | 1 | 2016 | 36 | 0.130 |
Why?
| | Hematopoiesis | 1 | 2017 | 170 | 0.130 |
Why?
| | Tissue Extracts | 2 | 2009 | 19 | 0.130 |
Why?
| | Gene Expression Regulation, Leukemic | 1 | 2016 | 48 | 0.130 |
Why?
| | Alcohol Oxidoreductases | 1 | 2016 | 37 | 0.130 |
Why?
| | Folic Acid | 1 | 2017 | 161 | 0.130 |
Why?
| | Pyrazoles | 2 | 2010 | 361 | 0.130 |
Why?
| | Heme Oxygenase (Decyclizing) | 2 | 2013 | 21 | 0.130 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 3 | 2013 | 85 | 0.130 |
Why?
| | Flow Cytometry | 2 | 2010 | 1065 | 0.130 |
Why?
| | Creatinine | 4 | 2005 | 434 | 0.130 |
Why?
| | Nuclear Magnetic Resonance, Biomolecular | 4 | 2011 | 237 | 0.130 |
Why?
| | Lipid Metabolism | 4 | 2019 | 438 | 0.130 |
Why?
| | Brain Concussion | 1 | 2023 | 478 | 0.130 |
Why?
| | Lipid Peroxidation | 3 | 2006 | 138 | 0.130 |
Why?
| | Familial Primary Pulmonary Hypertension | 1 | 2016 | 190 | 0.130 |
Why?
| | Neuroglia | 1 | 1996 | 148 | 0.130 |
Why?
| | Hernias, Diaphragmatic, Congenital | 1 | 2018 | 185 | 0.120 |
Why?
| | Nuclear Proteins | 2 | 2023 | 584 | 0.120 |
Why?
| | Hypothermia, Induced | 2 | 2006 | 65 | 0.120 |
Why?
| | Radiography | 2 | 2008 | 803 | 0.120 |
Why?
| | Indoles | 2 | 2015 | 296 | 0.120 |
Why?
| | Paracrine Communication | 1 | 2015 | 55 | 0.120 |
Why?
| | Methylamines | 2 | 2005 | 30 | 0.120 |
Why?
| | Oligomycins | 1 | 2014 | 7 | 0.120 |
Why?
| | Proto-Oncogene Proteins c-akt | 3 | 2018 | 394 | 0.120 |
Why?
| | Homeostasis | 1 | 2018 | 561 | 0.120 |
Why?
| | Pyridines | 1 | 2018 | 417 | 0.120 |
Why?
| | Hypertension, Pulmonary | 2 | 2016 | 1733 | 0.120 |
Why?
| | Mitochondrial Proton-Translocating ATPases | 1 | 2014 | 17 | 0.120 |
Why?
| | Fatty Acids, Unsaturated | 2 | 2005 | 84 | 0.120 |
Why?
| | Pentacyclic Triterpenes | 1 | 2014 | 13 | 0.120 |
Why?
| | Models, Animal | 2 | 2009 | 337 | 0.120 |
Why?
| | Ferric Compounds | 1 | 2014 | 41 | 0.120 |
Why?
| | ras Proteins | 2 | 2013 | 136 | 0.120 |
Why?
| | Fatty Acid Synthase, Type I | 1 | 2014 | 5 | 0.110 |
Why?
| | Rats, Inbred Lew | 4 | 2010 | 86 | 0.110 |
Why?
| | Prognosis | 4 | 2017 | 3318 | 0.110 |
Why?
| | Lipoxygenase Inhibitors | 1 | 2014 | 36 | 0.110 |
Why?
| | Leukotrienes | 1 | 2014 | 33 | 0.110 |
Why?
| | Convulsants | 1 | 2013 | 6 | 0.110 |
Why?
| | Dextrans | 2 | 2014 | 72 | 0.110 |
Why?
| | Kainic Acid | 1 | 2013 | 31 | 0.110 |
Why?
| | Fetal Growth Retardation | 1 | 2019 | 470 | 0.110 |
Why?
| | NAD | 2 | 2004 | 63 | 0.110 |
Why?
| | Propranolol | 1 | 2013 | 46 | 0.110 |
Why?
| | Brain Edema | 1 | 2013 | 52 | 0.110 |
Why?
| | Pregnancy | 6 | 2019 | 5490 | 0.110 |
Why?
| | Cell Survival | 4 | 2016 | 1004 | 0.110 |
Why?
| | Mice, Inbred BALB C | 4 | 2019 | 1136 | 0.110 |
Why?
| | Urothelium | 1 | 2013 | 33 | 0.110 |
Why?
| | Insulin | 3 | 2019 | 2076 | 0.110 |
Why?
| | Unfolded Protein Response | 1 | 2013 | 44 | 0.110 |
Why?
| | Azoxymethane | 1 | 2013 | 15 | 0.110 |
Why?
| | Diffusion Magnetic Resonance Imaging | 1 | 2013 | 83 | 0.110 |
Why?
| | Triple Negative Breast Neoplasms | 1 | 2015 | 157 | 0.110 |
Why?
| | Phosphorylation | 3 | 2013 | 1537 | 0.110 |
Why?
| | Severity of Illness Index | 2 | 2013 | 2530 | 0.110 |
Why?
| | Estrogens | 1 | 2015 | 311 | 0.100 |
Why?
| | DNA-Binding Proteins | 3 | 2016 | 1286 | 0.100 |
Why?
| | Grape Seed Extract | 1 | 2013 | 41 | 0.100 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2019 | 914 | 0.100 |
Why?
| | Equipment Design | 2 | 2019 | 496 | 0.100 |
Why?
| | Tumor Cells, Cultured | 3 | 2019 | 834 | 0.100 |
Why?
| | Feasibility Studies | 2 | 2019 | 737 | 0.100 |
Why?
| | Phytic Acid | 1 | 2012 | 41 | 0.100 |
Why?
| | Shock, Hemorrhagic | 1 | 2014 | 152 | 0.100 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 2 | 2015 | 103 | 0.100 |
Why?
| | Treatment Outcome | 8 | 2016 | 9006 | 0.100 |
Why?
| | Metabolic Diseases | 1 | 2013 | 98 | 0.100 |
Why?
| | Image Enhancement | 2 | 2010 | 158 | 0.100 |
Why?
| | Thiophenes | 1 | 2013 | 108 | 0.100 |
Why?
| | Reference Values | 3 | 2019 | 735 | 0.100 |
Why?
| | Mice, Transgenic | 6 | 2015 | 1925 | 0.100 |
Why?
| | Adult | 10 | 2013 | 30245 | 0.100 |
Why?
| | Glioblastoma | 1 | 2014 | 250 | 0.100 |
Why?
| | Reproducibility of Results | 5 | 2019 | 2752 | 0.100 |
Why?
| | Quinolines | 1 | 2013 | 127 | 0.100 |
Why?
| | Radionuclide Imaging | 1 | 2012 | 115 | 0.100 |
Why?
| | Sarcoma | 1 | 2013 | 137 | 0.100 |
Why?
| | Temperature | 3 | 2014 | 557 | 0.100 |
Why?
| | Electroencephalography | 1 | 2013 | 332 | 0.100 |
Why?
| | Proto-Oncogene Proteins | 2 | 2013 | 595 | 0.100 |
Why?
| | Antibodies, Monoclonal | 3 | 2023 | 1236 | 0.090 |
Why?
| | HSP70 Heat-Shock Proteins | 3 | 2010 | 61 | 0.090 |
Why?
| | Isotope Labeling | 1 | 2012 | 66 | 0.090 |
Why?
| | Tandem Mass Spectrometry | 2 | 2014 | 405 | 0.090 |
Why?
| | Urinary Bladder | 1 | 2013 | 163 | 0.090 |
Why?
| | Calcineurin | 1 | 2012 | 84 | 0.090 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2013 | 286 | 0.090 |
Why?
| | Models, Biological | 5 | 2013 | 1589 | 0.090 |
Why?
| | Tissue Distribution | 2 | 2003 | 280 | 0.090 |
Why?
| | Mice, Inbred NOD | 3 | 2019 | 551 | 0.090 |
Why?
| | Proteasome Inhibitors | 1 | 2011 | 41 | 0.090 |
Why?
| | Tacrolimus | 1 | 2012 | 133 | 0.090 |
Why?
| | Boronic Acids | 1 | 2011 | 33 | 0.090 |
Why?
| | Nucleotides | 2 | 2017 | 111 | 0.090 |
Why?
| | Benzimidazoles | 1 | 2011 | 137 | 0.090 |
Why?
| | Sciuridae | 2 | 2014 | 142 | 0.090 |
Why?
| | Phosphatidylinositol 3-Kinases | 3 | 2018 | 324 | 0.090 |
Why?
| | Pyrazines | 1 | 2011 | 70 | 0.090 |
Why?
| | Mice, Knockout | 5 | 2020 | 2523 | 0.090 |
Why?
| | Protease Inhibitors | 1 | 2011 | 96 | 0.090 |
Why?
| | Nitric Oxide Synthase Type II | 1 | 2010 | 156 | 0.090 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2016 | 533 | 0.090 |
Why?
| | Heart Ventricles | 1 | 2015 | 710 | 0.090 |
Why?
| | Hydroxybutyrates | 2 | 2010 | 11 | 0.090 |
Why?
| | Complement C3-C5 Convertases | 1 | 2010 | 19 | 0.090 |
Why?
| | Cricetulus | 1 | 2010 | 96 | 0.090 |
Why?
| | CHO Cells | 1 | 2010 | 135 | 0.080 |
Why?
| | Cognition Disorders | 1 | 2014 | 476 | 0.080 |
Why?
| | TRPP Cation Channels | 1 | 2010 | 63 | 0.080 |
Why?
| | Cricetinae | 1 | 2010 | 244 | 0.080 |
Why?
| | Epigenomics | 2 | 2020 | 98 | 0.080 |
Why?
| | Drug Delivery Systems | 2 | 2017 | 293 | 0.080 |
Why?
| | Fatty Acids, Monounsaturated | 2 | 2010 | 47 | 0.080 |
Why?
| | ErbB Receptors | 2 | 2015 | 553 | 0.080 |
Why?
| | Analysis of Variance | 2 | 2010 | 1208 | 0.080 |
Why?
| | Neoplasm Transplantation | 3 | 2019 | 227 | 0.080 |
Why?
| | Intestine, Small | 1 | 2010 | 121 | 0.080 |
Why?
| | Mutation | 3 | 2020 | 3313 | 0.080 |
Why?
| | Cysts | 1 | 2010 | 92 | 0.080 |
Why?
| | Ribose | 1 | 2009 | 18 | 0.080 |
Why?
| | Deoxyglucose | 1 | 2009 | 43 | 0.080 |
Why?
| | Dinoprost | 1 | 2009 | 30 | 0.080 |
Why?
| | Alanine | 2 | 2013 | 104 | 0.080 |
Why?
| | Cell Extracts | 1 | 2009 | 15 | 0.080 |
Why?
| | Sulfonamides | 2 | 2011 | 442 | 0.080 |
Why?
| | RNA, Neoplasm | 1 | 2009 | 81 | 0.080 |
Why?
| | Percussion | 1 | 2008 | 2 | 0.080 |
Why?
| | History, 21st Century | 1 | 2009 | 158 | 0.080 |
Why?
| | Gas Chromatography-Mass Spectrometry | 1 | 2009 | 118 | 0.080 |
Why?
| | Neurons | 1 | 1996 | 1261 | 0.080 |
Why?
| | Surgical Equipment | 1 | 2008 | 13 | 0.080 |
Why?
| | History, 20th Century | 1 | 2009 | 265 | 0.080 |
Why?
| | Oxygen | 2 | 2010 | 827 | 0.080 |
Why?
| | Systems Biology | 1 | 2009 | 54 | 0.080 |
Why?
| | Oxidation-Reduction | 3 | 2016 | 912 | 0.080 |
Why?
| | Critical Illness | 2 | 2011 | 653 | 0.080 |
Why?
| | Receptor, ErbB-3 | 1 | 2008 | 41 | 0.080 |
Why?
| | Macaca fascicularis | 4 | 2000 | 50 | 0.080 |
Why?
| | Complement C3d | 2 | 2023 | 60 | 0.070 |
Why?
| | Body Weight | 4 | 2012 | 853 | 0.070 |
Why?
| | Disease Progression | 5 | 2018 | 2364 | 0.070 |
Why?
| | Fluorouracil | 1 | 2008 | 151 | 0.070 |
Why?
| | Mice, Inbred C57BL | 5 | 2018 | 4617 | 0.070 |
Why?
| | Lymphocytes | 1 | 2009 | 321 | 0.070 |
Why?
| | Protein Transport | 1 | 2009 | 386 | 0.070 |
Why?
| | Triglycerides | 2 | 2010 | 464 | 0.070 |
Why?
| | DNA | 2 | 2009 | 1331 | 0.070 |
Why?
| | Area Under Curve | 1 | 2008 | 271 | 0.070 |
Why?
| | Heart-Assist Devices | 1 | 2013 | 493 | 0.070 |
Why?
| | Oxidative Phosphorylation | 2 | 2005 | 154 | 0.070 |
Why?
| | Age Factors | 2 | 2011 | 2875 | 0.070 |
Why?
| | MicroRNAs | 1 | 2013 | 598 | 0.070 |
Why?
| | Chromatin | 2 | 2020 | 418 | 0.070 |
Why?
| | Heterografts | 2 | 2019 | 117 | 0.070 |
Why?
| | Medical Oncology | 1 | 2009 | 229 | 0.070 |
Why?
| | X-Ray Microtomography | 2 | 2021 | 73 | 0.070 |
Why?
| | Polycystic Kidney, Autosomal Dominant | 1 | 2010 | 209 | 0.070 |
Why?
| | Tritium | 1 | 2006 | 66 | 0.070 |
Why?
| | ROC Curve | 1 | 2008 | 442 | 0.070 |
Why?
| | Body Temperature | 1 | 2007 | 176 | 0.070 |
Why?
| | Up-Regulation | 2 | 2006 | 794 | 0.070 |
Why?
| | Leukocytes, Mononuclear | 1 | 2009 | 487 | 0.070 |
Why?
| | Piperidines | 1 | 2007 | 159 | 0.070 |
Why?
| | Heat-Shock Response | 1 | 2006 | 46 | 0.070 |
Why?
| | Receptor, ErbB-2 | 1 | 2008 | 299 | 0.070 |
Why?
| | Nitrogen | 1 | 2007 | 143 | 0.070 |
Why?
| | Maximum Tolerated Dose | 3 | 2013 | 182 | 0.060 |
Why?
| | Alcohol Drinking | 1 | 2012 | 651 | 0.060 |
Why?
| | Survival Rate | 3 | 2019 | 1634 | 0.060 |
Why?
| | Liver Failure, Acute | 1 | 2006 | 58 | 0.060 |
Why?
| | Lung Injury | 1 | 2008 | 192 | 0.060 |
Why?
| | Deuterium | 1 | 2005 | 79 | 0.060 |
Why?
| | Allantoin | 1 | 2005 | 1 | 0.060 |
Why?
| | Betaine | 1 | 2005 | 63 | 0.060 |
Why?
| | Glutamic Acid | 2 | 2010 | 207 | 0.060 |
Why?
| | Inflammation | 3 | 2015 | 2444 | 0.060 |
Why?
| | Aged | 5 | 2013 | 18944 | 0.060 |
Why?
| | Seasons | 1 | 2007 | 437 | 0.060 |
Why?
| | Methionine | 1 | 2005 | 144 | 0.060 |
Why?
| | Hot Temperature | 1 | 2006 | 298 | 0.060 |
Why?
| | Lipids | 2 | 2021 | 558 | 0.060 |
Why?
| | Reference Standards | 2 | 2019 | 160 | 0.060 |
Why?
| | Heart Rate | 2 | 2009 | 705 | 0.060 |
Why?
| | Glutamates | 1 | 2004 | 55 | 0.060 |
Why?
| | Gene Expression Profiling | 3 | 2019 | 1510 | 0.060 |
Why?
| | Mitochondrial Encephalomyopathies | 1 | 2004 | 8 | 0.060 |
Why?
| | Biological Transport | 2 | 2015 | 363 | 0.060 |
Why?
| | Cholesterol | 1 | 2005 | 365 | 0.060 |
Why?
| | Free Radical Scavengers | 1 | 2004 | 78 | 0.060 |
Why?
| | Uric Acid | 1 | 2005 | 148 | 0.060 |
Why?
| | Proteins | 1 | 2009 | 890 | 0.060 |
Why?
| | Dacarbazine | 2 | 2014 | 99 | 0.060 |
Why?
| | Hypoxia-Ischemia, Brain | 1 | 2004 | 24 | 0.060 |
Why?
| | HSP72 Heat-Shock Proteins | 1 | 2003 | 26 | 0.050 |
Why?
| | RNA, Small Interfering | 2 | 2016 | 528 | 0.050 |
Why?
| | Calcineurin Inhibitors | 1 | 2003 | 57 | 0.050 |
Why?
| | Injections, Intravenous | 1 | 2003 | 195 | 0.050 |
Why?
| | Cardiac Output | 1 | 2003 | 139 | 0.050 |
Why?
| | Coronary Circulation | 1 | 2003 | 131 | 0.050 |
Why?
| | Wounds and Injuries | 1 | 2010 | 674 | 0.050 |
Why?
| | Gliosis | 1 | 2023 | 27 | 0.050 |
Why?
| | Mitochondria, Liver | 1 | 2003 | 67 | 0.050 |
Why?
| | Acetylcysteine | 1 | 2004 | 141 | 0.050 |
Why?
| | Mitochondria, Heart | 1 | 2003 | 72 | 0.050 |
Why?
| | Tyrosine | 1 | 2023 | 203 | 0.050 |
Why?
| | Necrosis | 3 | 2010 | 210 | 0.050 |
Why?
| | Protein Tyrosine Phosphatases | 1 | 2023 | 143 | 0.050 |
Why?
| | Adenocarcinoma | 1 | 2009 | 787 | 0.050 |
Why?
| | Middle Aged | 6 | 2016 | 26552 | 0.050 |
Why?
| | Models, Cardiovascular | 1 | 2003 | 175 | 0.050 |
Why?
| | Rupture | 1 | 2022 | 96 | 0.050 |
Why?
| | Reperfusion | 1 | 2002 | 35 | 0.050 |
Why?
| | Anterior Cruciate Ligament | 1 | 2022 | 79 | 0.050 |
Why?
| | Tumor Burden | 2 | 2014 | 257 | 0.050 |
Why?
| | Oxaloacetic Acid | 1 | 2001 | 2 | 0.050 |
Why?
| | AMP-Activated Protein Kinases | 2 | 2013 | 170 | 0.050 |
Why?
| | Aspartic Acid | 1 | 2001 | 77 | 0.050 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2023 | 382 | 0.050 |
Why?
| | Succinic Acid | 2 | 2013 | 38 | 0.050 |
Why?
| | Teratoma | 1 | 2022 | 92 | 0.050 |
Why?
| | Tibia | 1 | 2022 | 166 | 0.050 |
Why?
| | Microsomes, Liver | 1 | 2001 | 54 | 0.050 |
Why?
| | Positron Emission Tomography Computed Tomography | 1 | 2021 | 67 | 0.040 |
Why?
| | Drug Therapy, Combination | 3 | 2016 | 944 | 0.040 |
Why?
| | Random Allocation | 3 | 2006 | 326 | 0.040 |
Why?
| | Phenotype | 3 | 2016 | 2754 | 0.040 |
Why?
| | gamma-Aminobutyric Acid | 1 | 2001 | 141 | 0.040 |
Why?
| | Heart Failure | 1 | 2013 | 1955 | 0.040 |
Why?
| | Ligands | 2 | 2012 | 553 | 0.040 |
Why?
| | Astrocytoma | 1 | 2020 | 106 | 0.040 |
Why?
| | Brain Stem Neoplasms | 1 | 2020 | 84 | 0.040 |
Why?
| | Hematinics | 1 | 2019 | 17 | 0.040 |
Why?
| | Pregnancy Complications | 1 | 2004 | 427 | 0.040 |
Why?
| | Tunica Intima | 1 | 2000 | 78 | 0.040 |
Why?
| | Cell Movement | 2 | 2015 | 852 | 0.040 |
Why?
| | Knee Joint | 1 | 2022 | 321 | 0.040 |
Why?
| | Enzyme Activation | 2 | 2013 | 752 | 0.040 |
Why?
| | Sheep, Domestic | 1 | 2019 | 33 | 0.040 |
Why?
| | Mice, SCID | 1 | 2019 | 311 | 0.040 |
Why?
| | Fluorescent Antibody Technique | 2 | 2013 | 383 | 0.040 |
Why?
| | Chromatography, Liquid | 1 | 2000 | 339 | 0.040 |
Why?
| | Mouth Mucosa | 1 | 2019 | 78 | 0.040 |
Why?
| | Drug Administration Schedule | 2 | 2013 | 712 | 0.040 |
Why?
| | Radiology, Interventional | 1 | 2019 | 26 | 0.040 |
Why?
| | Survival Analysis | 2 | 2016 | 1203 | 0.040 |
Why?
| | Lysine | 1 | 2020 | 240 | 0.040 |
Why?
| | Transplantation, Homologous | 1 | 2000 | 373 | 0.040 |
Why?
| | Child | 3 | 2023 | 18340 | 0.040 |
Why?
| | Amino Acids | 1 | 2002 | 443 | 0.040 |
Why?
| | Salivary Glands | 1 | 2018 | 20 | 0.040 |
Why?
| | Mifepristone | 1 | 2018 | 59 | 0.040 |
Why?
| | Carcinoma, Adenoid Cystic | 1 | 2018 | 16 | 0.040 |
Why?
| | Lung Neoplasms | 1 | 2010 | 2148 | 0.040 |
Why?
| | Anthropometry | 1 | 2019 | 182 | 0.040 |
Why?
| | NF-kappa B | 2 | 2013 | 615 | 0.040 |
Why?
| | Breast | 1 | 2019 | 138 | 0.040 |
Why?
| | Phantoms, Imaging | 1 | 2019 | 123 | 0.040 |
Why?
| | Weight Gain | 1 | 2001 | 454 | 0.040 |
Why?
| | Immunohistochemistry | 2 | 2012 | 1604 | 0.040 |
Why?
| | Citric Acid Cycle | 1 | 1997 | 42 | 0.040 |
Why?
| | Robotics | 1 | 2019 | 77 | 0.040 |
Why?
| | Cell Size | 1 | 1997 | 79 | 0.040 |
Why?
| | Digoxin | 1 | 2017 | 26 | 0.040 |
Why?
| | Pentose Phosphate Pathway | 1 | 2017 | 46 | 0.040 |
Why?
| | Cysteine | 1 | 2018 | 172 | 0.040 |
Why?
| | Aorta | 1 | 2000 | 377 | 0.030 |
Why?
| | Cytosol | 1 | 1997 | 199 | 0.030 |
Why?
| | Diet, High-Fat | 1 | 2018 | 224 | 0.030 |
Why?
| | Vascular Endothelial Growth Factor Receptor-1 | 2 | 2010 | 67 | 0.030 |
Why?
| | Image Interpretation, Computer-Assisted | 1 | 2019 | 225 | 0.030 |
Why?
| | Rabbits | 1 | 2018 | 713 | 0.030 |
Why?
| | Nanomedicine | 1 | 2017 | 27 | 0.030 |
Why?
| | Hydrazines | 1 | 2016 | 27 | 0.030 |
Why?
| | Benzothiazoles | 1 | 2016 | 31 | 0.030 |
Why?
| | Lymph Nodes | 1 | 2019 | 412 | 0.030 |
Why?
| | Carbon | 1 | 2017 | 155 | 0.030 |
Why?
| | Adventitia | 1 | 2016 | 37 | 0.030 |
Why?
| | Heat Shock Transcription Factors | 2 | 2006 | 17 | 0.030 |
Why?
| | Gestational Age | 1 | 2019 | 762 | 0.030 |
Why?
| | Phenylurea Compounds | 1 | 2016 | 81 | 0.030 |
Why?
| | Membrane Lipids | 1 | 1996 | 84 | 0.030 |
Why?
| | Epigenesis, Genetic | 1 | 2020 | 515 | 0.030 |
Why?
| | Risk Factors | 1 | 2009 | 8606 | 0.030 |
Why?
| | Transforming Growth Factor beta | 1 | 2018 | 435 | 0.030 |
Why?
| | Cell Hypoxia | 1 | 2016 | 220 | 0.030 |
Why?
| | Animals, Newborn | 1 | 1997 | 769 | 0.030 |
Why?
| | Fatty Acid Transport Proteins | 1 | 2015 | 18 | 0.030 |
Why?
| | Epoxy Compounds | 1 | 2015 | 31 | 0.030 |
Why?
| | Stem Cell Niche | 1 | 2015 | 41 | 0.030 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2020 | 848 | 0.030 |
Why?
| | Precision Medicine | 1 | 2019 | 335 | 0.030 |
Why?
| | Carnitine O-Palmitoyltransferase | 1 | 2015 | 43 | 0.030 |
Why?
| | Dihydrolipoyllysine-Residue Acetyltransferase | 1 | 2014 | 6 | 0.030 |
Why?
| | Ketone Oxidoreductases | 1 | 2014 | 7 | 0.030 |
Why?
| | Lipoprotein Lipase | 1 | 2015 | 54 | 0.030 |
Why?
| | Sodium Hydroxide | 1 | 2014 | 8 | 0.030 |
Why?
| | Membrane Potential, Mitochondrial | 1 | 2014 | 55 | 0.030 |
Why?
| | Software | 1 | 2019 | 525 | 0.030 |
Why?
| | Half-Life | 1 | 2014 | 140 | 0.030 |
Why?
| | Radiopharmaceuticals | 1 | 2015 | 158 | 0.030 |
Why?
| | Gene Knockdown Techniques | 1 | 2015 | 298 | 0.030 |
Why?
| | Recovery of Function | 1 | 2018 | 567 | 0.030 |
Why?
| | Bone Marrow | 1 | 2015 | 242 | 0.030 |
Why?
| | Pyrroles | 1 | 2015 | 179 | 0.030 |
Why?
| | Neoplasm Invasiveness | 1 | 2015 | 435 | 0.030 |
Why?
| | Superoxides | 1 | 2014 | 186 | 0.030 |
Why?
| | Tissue Donors | 2 | 2010 | 313 | 0.030 |
Why?
| | Maze Learning | 1 | 2014 | 86 | 0.030 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2014 | 168 | 0.030 |
Why?
| | Mice, Mutant Strains | 1 | 2014 | 271 | 0.030 |
Why?
| | Enzyme Induction | 1 | 2013 | 81 | 0.030 |
Why?
| | Cell Differentiation | 1 | 2020 | 1681 | 0.030 |
Why?
| | beta-Galactosidase | 1 | 2013 | 62 | 0.030 |
Why?
| | Transcriptome | 1 | 2019 | 719 | 0.030 |
Why?
| | Particle Size | 1 | 2014 | 310 | 0.030 |
Why?
| | Breeding | 1 | 2013 | 54 | 0.030 |
Why?
| | Mice, Inbred A | 1 | 2013 | 45 | 0.030 |
Why?
| | Amino Acids, Aromatic | 1 | 2013 | 8 | 0.030 |
Why?
| | Antineoplastic Agents, Alkylating | 1 | 2013 | 68 | 0.030 |
Why?
| | RNA, Messenger | 2 | 2013 | 2507 | 0.030 |
Why?
| | Catalysis | 1 | 2014 | 288 | 0.030 |
Why?
| | Somatomedins | 1 | 2013 | 28 | 0.030 |
Why?
| | Vacuoles | 1 | 2013 | 32 | 0.030 |
Why?
| | Staining and Labeling | 1 | 2013 | 133 | 0.030 |
Why?
| | Keratins | 1 | 2013 | 163 | 0.030 |
Why?
| | Hyperplasia | 1 | 2013 | 163 | 0.030 |
Why?
| | Cell Shape | 1 | 2013 | 53 | 0.030 |
Why?
| | Mitogens | 1 | 2013 | 56 | 0.030 |
Why?
| | RNA Interference | 1 | 2014 | 426 | 0.030 |
Why?
| | Mitochondrial Proteins | 1 | 2014 | 212 | 0.030 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2013 | 76 | 0.030 |
Why?
| | Immunoenzyme Techniques | 1 | 2013 | 191 | 0.030 |
Why?
| | Adenoviridae | 1 | 2013 | 179 | 0.030 |
Why?
| | Glucose Transporter Type 4 | 1 | 2012 | 36 | 0.030 |
Why?
| | Integrases | 1 | 2013 | 116 | 0.030 |
Why?
| | Carcinogens | 1 | 2013 | 101 | 0.030 |
Why?
| | Neoplasm Grading | 1 | 2013 | 241 | 0.030 |
Why?
| | Transplantation, Heterologous | 1 | 2013 | 180 | 0.030 |
Why?
| | Long-Term Potentiation | 1 | 2014 | 145 | 0.030 |
Why?
| | Decision Making | 1 | 2019 | 761 | 0.030 |
Why?
| | Epidermal Growth Factor | 1 | 2013 | 160 | 0.030 |
Why?
| | Estradiol | 1 | 2015 | 450 | 0.030 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2013 | 155 | 0.030 |
Why?
| | Colorado | 1 | 2022 | 4061 | 0.030 |
Why?
| | Molecular Chaperones | 1 | 2013 | 156 | 0.020 |
Why?
| | RNA, Untranslated | 1 | 2013 | 112 | 0.020 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2013 | 262 | 0.020 |
Why?
| | Gene Regulatory Networks | 1 | 2013 | 229 | 0.020 |
Why?
| | Mice, Inbred MRL lpr | 1 | 2011 | 37 | 0.020 |
Why?
| | Sucrose | 1 | 2012 | 92 | 0.020 |
Why?
| | Neutrophils | 2 | 2006 | 1072 | 0.020 |
Why?
| | Self Administration | 1 | 2012 | 122 | 0.020 |
Why?
| | beta Catenin | 1 | 2013 | 208 | 0.020 |
Why?
| | Adenine | 1 | 2013 | 217 | 0.020 |
Why?
| | Bortezomib | 1 | 2011 | 41 | 0.020 |
Why?
| | Fatigue | 1 | 2013 | 292 | 0.020 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2013 | 191 | 0.020 |
Why?
| | Kidney Glomerulus | 1 | 2011 | 100 | 0.020 |
Why?
| | Protein Biosynthesis | 1 | 2013 | 375 | 0.020 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2013 | 739 | 0.020 |
Why?
| | Nestin | 1 | 2010 | 16 | 0.020 |
Why?
| | Intermediate Filament Proteins | 1 | 2010 | 57 | 0.020 |
Why?
| | Urethane | 1 | 2010 | 40 | 0.020 |
Why?
| | Receptors, Complement 3d | 1 | 2011 | 129 | 0.020 |
Why?
| | Proteasome Endopeptidase Complex | 1 | 2011 | 132 | 0.020 |
Why?
| | Immunoblotting | 1 | 2011 | 277 | 0.020 |
Why?
| | Mesenteric Arteries | 1 | 2010 | 16 | 0.020 |
Why?
| | Cluster Analysis | 1 | 2011 | 448 | 0.020 |
Why?
| | HT29 Cells | 1 | 2010 | 35 | 0.020 |
Why?
| | Kidney Function Tests | 1 | 2010 | 139 | 0.020 |
Why?
| | Hydrogen | 1 | 2010 | 59 | 0.020 |
Why?
| | Caspase 3 | 1 | 2011 | 227 | 0.020 |
Why?
| | Aged, 80 and over | 2 | 2013 | 6296 | 0.020 |
Why?
| | Ki-67 Antigen | 1 | 2010 | 101 | 0.020 |
Why?
| | Limit of Detection | 1 | 2009 | 53 | 0.020 |
Why?
| | Hippocampus | 1 | 2014 | 688 | 0.020 |
Why?
| | Transplantation Conditioning | 1 | 2010 | 146 | 0.020 |
Why?
| | Portal Vein | 1 | 2010 | 75 | 0.020 |
Why?
| | Capillary Permeability | 1 | 2010 | 134 | 0.020 |
Why?
| | Constriction, Pathologic | 1 | 2010 | 205 | 0.020 |
Why?
| | STAT3 Transcription Factor | 1 | 2010 | 171 | 0.020 |
Why?
| | Citrates | 1 | 2009 | 41 | 0.020 |
Why?
| | Gene Deletion | 1 | 2010 | 351 | 0.020 |
Why?
| | Cell Cycle | 1 | 2011 | 538 | 0.020 |
Why?
| | Bronchoscopy | 2 | 2000 | 193 | 0.020 |
Why?
| | Celecoxib | 1 | 2008 | 38 | 0.020 |
Why?
| | Infusions, Intravenous | 1 | 2010 | 368 | 0.020 |
Why?
| | Capecitabine | 1 | 2008 | 45 | 0.020 |
Why?
| | Free Radicals | 1 | 2009 | 98 | 0.020 |
Why?
| | Dura Mater | 1 | 2008 | 27 | 0.020 |
Why?
| | Genotype | 1 | 2013 | 1733 | 0.020 |
Why?
| | Principal Component Analysis | 1 | 2009 | 174 | 0.020 |
Why?
| | Mammary Tumor Virus, Mouse | 1 | 2008 | 42 | 0.020 |
Why?
| | Mammary Neoplasms, Animal | 1 | 2008 | 28 | 0.020 |
Why?
| | Down-Regulation | 1 | 2010 | 593 | 0.020 |
Why?
| | Craniotomy | 1 | 2008 | 66 | 0.020 |
Why?
| | Drug Discovery | 1 | 2009 | 122 | 0.020 |
Why?
| | Hypoglycemic Agents | 1 | 2015 | 1006 | 0.020 |
Why?
| | Ethanol | 1 | 2012 | 532 | 0.020 |
Why?
| | Pressure | 1 | 2008 | 214 | 0.020 |
Why?
| | Transcription, Genetic | 1 | 2013 | 1282 | 0.020 |
Why?
| | Child, Preschool | 1 | 2020 | 9093 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2010 | 496 | 0.020 |
Why?
| | Nerve Tissue Proteins | 1 | 2010 | 521 | 0.020 |
Why?
| | Carcinoma | 1 | 2008 | 198 | 0.020 |
Why?
| | Peroxidase | 1 | 2006 | 160 | 0.020 |
Why?
| | Aspartate Aminotransferases | 1 | 2006 | 84 | 0.020 |
Why?
| | Risk | 1 | 2008 | 807 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2013 | 2993 | 0.020 |
Why?
| | Pilot Projects | 1 | 2010 | 1356 | 0.020 |
Why?
| | Intensive Care Units | 1 | 2010 | 620 | 0.020 |
Why?
| | Alanine Transaminase | 1 | 2006 | 140 | 0.020 |
Why?
| | Organ Size | 1 | 2006 | 420 | 0.020 |
Why?
| | Cytokines | 1 | 2013 | 1795 | 0.020 |
Why?
| | Membrane Transport Proteins | 1 | 2006 | 136 | 0.020 |
Why?
| | Intestinal Mucosa | 1 | 2010 | 528 | 0.020 |
Why?
| | Cerebral Cortex | 1 | 2008 | 375 | 0.020 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2010 | 654 | 0.020 |
Why?
| | HSP27 Heat-Shock Proteins | 1 | 2005 | 11 | 0.020 |
Why?
| | Quercetin | 1 | 2005 | 11 | 0.020 |
Why?
| | Computational Biology | 1 | 2009 | 527 | 0.020 |
Why?
| | Dietary Fats | 1 | 2006 | 286 | 0.010 |
Why?
| | Transplantation, Isogeneic | 1 | 2003 | 17 | 0.010 |
Why?
| | Raffinose | 1 | 2003 | 18 | 0.010 |
Why?
| | Allopurinol | 1 | 2003 | 53 | 0.010 |
Why?
| | Organ Preservation Solutions | 1 | 2003 | 37 | 0.010 |
Why?
| | Protein Binding | 1 | 2009 | 1867 | 0.010 |
Why?
| | Transcriptional Activation | 1 | 2005 | 331 | 0.010 |
Why?
| | Cell Membrane | 1 | 2006 | 663 | 0.010 |
Why?
| | Basic Helix-Loop-Helix Transcription Factors | 1 | 2004 | 222 | 0.010 |
Why?
| | Adenosine | 1 | 2003 | 202 | 0.010 |
Why?
| | Preoperative Care | 1 | 2004 | 318 | 0.010 |
Why?
| | Trans-Activators | 1 | 2004 | 356 | 0.010 |
Why?
| | Lipopolysaccharides | 1 | 2005 | 802 | 0.010 |
Why?
| | Gene Expression | 1 | 2006 | 1397 | 0.010 |
Why?
| | Automation | 1 | 2000 | 74 | 0.010 |
Why?
| | Calibration | 1 | 2000 | 125 | 0.010 |
Why?
| | Microchemistry | 1 | 2000 | 15 | 0.010 |
Why?
| | Receptors, Interleukin-2 | 1 | 2000 | 64 | 0.010 |
Why?
| | Emulsions | 1 | 2000 | 42 | 0.010 |
Why?
| | Autopsy | 1 | 2000 | 84 | 0.010 |
Why?
| | Blood | 1 | 2000 | 93 | 0.010 |
Why?
| | Prospective Studies | 1 | 2010 | 6189 | 0.010 |
Why?
| | Postoperative Period | 1 | 2000 | 289 | 0.010 |
Why?
| | Chronic Disease | 1 | 2004 | 1570 | 0.010 |
Why?
| | Immune Tolerance | 1 | 2000 | 321 | 0.010 |
Why?
| | Regression Analysis | 1 | 2000 | 932 | 0.010 |
Why?
| | Recombinant Fusion Proteins | 1 | 2000 | 599 | 0.010 |
Why?
| | Biopsy | 1 | 2000 | 1024 | 0.010 |
Why?
| | Sensitivity and Specificity | 1 | 2000 | 1682 | 0.010 |
Why?
|
|
Serkova's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|